{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:47:48Z","timestamp":1794941268086,"version":"4.9.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009418","name":"Nordsj\u00e6llands Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Thyrotoxic periodic paralysis (TPP) is a rare condition characterized by muscle paralysis, thyrotoxicosis, and hypokalemia. It presents with paralysis of both proximal and distal musculature in upper and lower limbs and may affect respiratory musculature and the cardiac conduction system. Early diagnosis is essential, as the condition is potentially reversible by oral or intravenous potassium treatment, leading to rapid resolution without lasting weakness. Overlooking the diagnosis may result in respiratory failure and cardiac arrhythmias including QT prolongation, Torsades de points, and ventricular arrhythmias.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 19-year-old Caucasian man was admitted acutely with paralysis in upper and lower limbs and tachycardia. Over several months, he had experienced anxiousness, sweating more than usual, had daily palpitations, shortness of breath on exertion, and loose stools, and had lost 21\u2009kg over the last year. Initial blood gas showed very low potassium of 1.4\u2009mM, and blood tests showed decreased Thyroid-stimulating hormone (TSH) &lt;\u20090.01\u2009\u00d7\u200910<jats:sup>\u2212\u20093<\/jats:sup> IU\/L, elevated free thyroxine (fT4) of 63.5 pM (reference interval (RI): 12.0\u201322.0 pM), and elevated total triiodothyronine (T3) of 8.2\u2009nM (RI: 1.0\u20132.6\u2009nM). He was diagnosed with TPP and treated with liquid oral potassium chloride (30\u2009mmol every 30\u2009minutes) and propylthiouracil (initial dose of 400\u2009mg followed by 200\u2009mg three times daily). TSH-receptor antibodies (TRAB) and thyroid-peroxidase antibodies (TPO-ab) were highly elevated. Thyroid ultrasound showed a normal-sized gland and color Doppler sonography showed increased vascularity throughout the gland, compatible with Graves\u2019 disease. He was discharged on day 4 with a normal potassium level and followed in the outpatient clinic where he received standard care for Graves\u2019 disease. Genetic testing using whole-genome sequencing found no genetic variants in genes previously associated with TPP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>TPP is very rare in Caucasians but more often affects young men in East Asian populations. The case presents a Caucasian man with TPP where genetic testing of <jats:italic>CACNA1S<\/jats:italic>, <jats:italic>KCNJ18<\/jats:italic>, <jats:italic>SCN4A<\/jats:italic>, <jats:italic>KCNJ2<\/jats:italic>, <jats:italic>KCNE3<\/jats:italic>, and <jats:italic>ABCC8<\/jats:italic> shows no pathogenic variants in genes previously associated with TPP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13044-023-00152-w","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:02:17Z","timestamp":1682899337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Thyrotoxic periodic paralysis in a Caucasian man without identifiable genetic predisposition: a case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Arne","family":"Heydorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Bertelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fana Louise Mortansd\u00f3ttir","family":"Nols\u00f6e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Eiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Lommer","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"152_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5740509","volume":"2018","author":"YK Bao","year":"2018","unstructured":"Bao YK, Ganesan VC, Rapp R, Bao SS. Bilateral lower extremity paralysis in a Caucasian male presenting to the emergency department. Case Rep Emerg Med. 2018;2018:1\u20133. https:\/\/doi.org\/10.1155\/2018\/5740509.","journal-title":"Case Rep Emerg Med"},{"key":"152_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/diagnostics10050316","volume":"10","author":"S Bilha","year":"2020","unstructured":"Bilha S, Mitu O, Teodoriu L, Haba C, Preda C. Thyrotoxic periodic paralysis\u2014a misleading challenge in the emergency department. Diagnostics. 2020;10:316. https:\/\/doi.org\/10.3390\/diagnostics10050316.","journal-title":"Diagnostics"},{"key":"152_CR3","doi-asserted-by":"publisher","first-page":"116794","DOI":"10.1016\/j.jns.2020.116794","volume":"412","author":"SC Cannon","year":"2020","unstructured":"Cannon SC. Further evidence for shared genetic susceptibility in both sporadic and Thyrotoxic periodic paralysis. J Neurol Sci. 2020;412:116794. https:\/\/doi.org\/10.1016\/j.jns.2020.116794.","journal-title":"J Neurol Sci"},{"key":"152_CR4","doi-asserted-by":"publisher","first-page":"27425","DOI":"10.1074\/jbc.M111.249656","volume":"286","author":"C-J Cheng","year":"2011","unstructured":"Cheng C-J, Lin S-H, Lo Y-F, Yang S-S, Hsu Y-J, Cannon SC, et al. Identification and functional characterization of Kir2.6 mutations associated with non-familial hypokalemic periodic paralysis. J Biol Chem. 2011;286:27425\u201335. https:\/\/doi.org\/10.1074\/jbc.M111.249656.","journal-title":"J Biol Chem"},{"key":"152_CR5","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1210\/jc.2002-020698","volume":"87","author":"MR Dias Da Silva","year":"2002","unstructured":"Dias Da Silva MR, Cerutti JM, Arnaldi LAT, Maciel RMB. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab. 2002;87:4881\u20134. https:\/\/doi.org\/10.1210\/jc.2002-020698.","journal-title":"J Clin Endocrinol Metab"},{"key":"152_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/B978-0-444-64076-5.00032-6","volume-title":"Handbook of clinical neurology","author":"D Fialho","year":"2018","unstructured":"Fialho D, Griggs RC, Matthews E. Periodic paralysis. In: Handbook of clinical neurology: Elsevier; 2018. p. 505\u201320. https:\/\/doi.org\/10.1016\/B978-0-444-64076-5.00032-6."},{"issue":"12","key":"152_CR7","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2174\/1871530321666210719114937","volume":"21","author":"CY Gbefon","year":"2021","unstructured":"Gbefon CY, Sobral CPS, Caldas A, Rocha VCC, Azulay RSS, Nascimento GC, et al. Genetic screening of patients with Thyrotoxic hypokalemic periodic paralysis: an experience from a tertiary Care Hospital in the Northeast of Brazil. Endocr Metab Immune Disord Drug Targets. 2021;21(12):2231\u20137. https:\/\/doi.org\/10.2174\/1871530321666210719114937 PMID: 34554906.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"152_CR8","unstructured":"Haider M, Chachar AZK, Munir A. Thyrotoxic periodic paralysis. J Ayub Med Coll Abbottabad. 2019;31(4):619\u201321."},{"key":"152_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/20009666.2017.1316906","volume":"7","author":"M Meseeha","year":"2017","unstructured":"Meseeha M, Parsamehr B, Kissell K, Attia M. Thyrotoxic periodic paralysis: a case study and review of the literature. J Community Hosp Intern Med Perspect. 2017;7:103\u20136. https:\/\/doi.org\/10.1080\/20009666.2017.1316906.","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"152_CR10","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1210\/jc.2019-00672","volume":"104","author":"S Noso","year":"2019","unstructured":"Noso S, Babaya N, Hiromine Y, Ito H, Taketomo Y, Yoshida S, et al. Contribution of Asian haplotype of KCNJ18 to susceptibility to and ethnic differences in Thyrotoxic periodic paralysis. J Clin Endocrinol Metab. 2019;104:6338\u201344. https:\/\/doi.org\/10.1210\/jc.2019-00672.","journal-title":"J Clin Endocrinol Metab"},{"key":"152_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/s-0042-119527","volume":"125","author":"S Park","year":"2017","unstructured":"Park S, Kim TY, Sim S, Oh H-S, Song E, Kim M, et al. Association of KCNJ2 genetic variants with susceptibility to Thyrotoxic periodic paralysis in patients with graves\u2019 disease. J Ger Soc Endocrinol Ger Diabetes. 2017;125:75\u20138. https:\/\/doi.org\/10.1055\/s-0042-119527.","journal-title":"J Ger Soc Endocrinol Ger Diabetes"},{"issue":"2","key":"152_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/0885066609358849","volume":"25","author":"P Pothiwala","year":"2010","unstructured":"Pothiwala P, Levine SN. Analytic review: Thyrotoxic periodic paralysis: a review. J Intensive Care Med. 2010;25(2):71\u20137. https:\/\/doi.org\/10.1177\/0885066609358849.","journal-title":"J Intensive Care Med"},{"key":"152_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1177\/0004563218785395","volume":"55","author":"E Rasheed","year":"2018","unstructured":"Rasheed E, Seheult J, Gibney J, Boran G. Does thyrotoxic periodic paralysis have a genetic predisposition? A case report. Ann Clin Biochem Int J Lab Med. 2018;55:713\u20136. https:\/\/doi.org\/10.1177\/0004563218785395.","journal-title":"Ann Clin Biochem Int J Lab Med"},{"key":"152_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1530\/JME-14-0083","volume":"53","author":"ALR Rolim","year":"2014","unstructured":"Rolim ALR, Lindsey SC, Kunii IS, Crispim F, Mois\u00e9s RCMS, Maciel RMB, et al. The insulin-sensitivity sulphonylurea receptor variant is associated with thyrotoxic paralysis. J Mol Endocrinol. 2014;53:295\u2013301. https:\/\/doi.org\/10.1530\/JME-14-0083.","journal-title":"J Mol Endocrinol"},{"key":"152_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cell.2009.12.024","volume":"140","author":"DP Ryan","year":"2010","unstructured":"Ryan DP, Dias da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AWC, et al. Mutations in Potassium Channel Kir2.6 cause susceptibility to Thyrotoxic hypokalemic periodic paralysis. Cell. 2010;140:88\u201398. https:\/\/doi.org\/10.1016\/j.cell.2009.12.024.","journal-title":"Cell"},{"key":"152_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/314262","volume":"2014","author":"TK Thethi","year":"2014","unstructured":"Thethi TK, Parks R, Katalenich B, Chhabra P, McCaw J, Syu S, et al. Case of Thyrotoxic periodic paralysis in a Caucasian male and review of literature. Case Rep Med. 2014;2014:1\u20135. https:\/\/doi.org\/10.1155\/2014\/314262.","journal-title":"Case Rep Med"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-023-00152-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-023-00152-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-023-00152-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:02:22Z","timestamp":1682899342000},"score":1,"resource":{"primary":{"URL":"https:\/\/thyroidresearchjournal.biomedcentral.com\/articles\/10.1186\/s13044-023-00152-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1186\/s13044-023-00152-w","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"21 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}